Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Alector Inc's innovative approach in targeting the transferrin receptor (TfR) for neurodegenerative treatments demonstrates substantial potential, with its ABC platform showing impressive brain uptake rates of 18-32 times in non-human primates while maintaining favorable safety profiles. The firm's pipeline, which includes promising candidates like AL137 and AL050, aims to tackle significant indications in Alzheimer’s disease and Parkinson’s, enhancing the likelihood of successful clinical outcomes supported by standardized AD biomarkers. Additionally, the potential for early clinical proof-of-concept data from these programs could provide considerable upside for shareholder value, further solidifying a positive outlook on the company’s prospects.

Bears say

Alector Inc. faces significant headwinds due to the failure of its INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and raises concerns about the efficacy of the company's therapeutic approach to neurodegeneration. This result introduces translational biology risks and highlights the inefficiency of PGRN transport, which undermines investor confidence in the potential success of other pipeline products such as AL001 and AL002. Additionally, ongoing clinical trials present company-specific risks that could further delay regulatory approvals and hinder the anticipated commercial revenue, contributing to a negative outlook for Alector's stock.

Alector Inc (ALEC) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 5 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.